# ğŸ§­ MANAGER ANSWERS TO ZO â€“ SAE OPERATIONAL PLAYBOOK (AUTHORITATIVE)

Date: January 13, 2025  
Owner: SR (Manager)  
Context: Align Section 19 (SAEâ†’Evo2â†’S/P/E) with nonâ€‘hallucinatory delivery for Ayesha (Stage IVB ovarian)

---

## Priority Answers (Top 5)

### P1) Missing NGS â€“ What do we show TODAY?
- Policy: Show proactive, deterministic guidance only. No SAEâ€‘driven drug inferences until tumor data exists.
- TODAY deliverables for Ayesha:
  - SOC card (carboplatin + paclitaxel; bevacizumab rationale for ascites/peritoneal).
  - Trials list (frontline, NYC) with transparent eligibility reasoning and confidence gates.
  - CAâ€‘125 monitoring plan (cycleâ€‘3 â‰¥70% drop, cycleâ€‘6 â‰¥90%, target <35; resistance: onâ€‘therapy rise or <50% at cycleâ€‘3).
  - Nextâ€‘test recommender (order of operations): 1) HRD (MyChoice/tissue), 2) ctDNA for MSI/TMB + somatic HRR, 3) SLFN11 IHC (PARP sensitivity), 4) ABCB1 proxy if prior taxane becomes relevant.
  - Mechanism Map: hidden (or grey â€œAwaiting NGSâ€). Hint tiles limited to test order, trials lever, monitoring; no â€œtry/avoidâ€ drug hints yet.

### P2) SAE thresholds â€“ source and policy
- Bands not single points; avoid brittle hard gates.
- Thresholds (calibrated bands; use hysteresis Â±0.05 to avoid flapping):
  - dna_repair_capacity: high â‰¥0.70; moderate 0.40â€“0.69; low <0.40.
  - pathway_burden.mapk/pi3k/vegf: high â‰¥0.70; moderate 0.40â€“0.69; low <0.40.
  - essentiality_signal: high â‰¥0.80 (stricter); moderate 0.50â€“0.79.
  - cross_resistance_risk: high >0.70; moderate 0.40â€“0.70.
  - cohort_overlap: high â‰¥0.70; moderate 0.40â€“0.69; low <0.40.
- Sources: literature anchors (GOGâ€‘218/ICON7, PAOLAâ€‘1), internal calibration on retrospective cases, oncologist consensus. Treat as policy constants; log for future recalibration.

### P3) Gemini trial tagging â€“ reliability policy
- Offline only; never in runtime paths. Validation protocol:
  - Batch tag 200 ovarian trials â†’ human spotâ€‘review 30 diverse trials.
  - Accept batch if â‰¥90% tag accuracy; otherwise adjust prompt taxonomy and reâ€‘tag.
  - Persist `model`, `version`, `parsed_at`, `reviewed_by`, `source_checksum` with each record.
  - Update cadence: weekly diff for new/changed trials. Uncertain tags default to neutral vector; never force a mechanism label.

### P4) Mechanism fit vs eligibility â€“ tiebreak rules
- Ranking: score = eligibility Î±=0.7 + mechanism_fit Î²=0.3 (conservative weighting).
- Guardrails:
  - Minimum eligibility threshold to enter topâ€‘10: â‰¥0.60.
  - Minimum mechanism_fit for mechanismâ€‘gated display: â‰¥0.50; if <0.50, show but without mechanism boost and add â€œlow mechanism fitâ€ warning.
  - Never suppress SOC; SOC card remains firstâ€‘class.
  - Provide â€œShow all trialsâ€ toggle for clinician control.

### P5) Hint tile language â€“ tone policy
- Use suggestive, RUOâ€‘appropriate tone (avoids paternalism; increases adoption):
  - â€œConsider ordering HRD (impacts PARP eligibility).â€
  - â€œConsider PARP + bevacizumab (ascites/peritoneal).â€
  - â€œConsider avoiding reâ€‘taxane (crossâ€‘resistance risk).â€
- Max 4 tiles; priority order: Next test â†’ Trials lever â†’ Monitoring â†’ Avoid (only if applicable). No â€œavoidâ€ tile for treatmentâ€‘naive.

---

## Claimâ€‘Level Answers (Operationalized)

### C1) DNA_repair_capacity high + ascites â†’ platinum Â± bevacizumab; PARP maintenance if HRDâ‰¥42; ATR/CHK1 on resistance
- Feature definition: dna_repair_capacity = 0.6Ã—DDR_burden + 0.2Ã—essentiality_signal (if HRR gene) + 0.2Ã—exon_disruption (if pathogenic HRR variant present). Else fall back to DDR_burden.
- Banding behavior: High â‡’ display clinician hint and allow modest trial boost for platinum Â± bevacizumab arms (+0.10); moderate â‡’ hint only; low â‡’ no hint.
- Resistance detection: trigger when any two of:
  - HRD drop â‰¥10 points vs baseline,
  - dna_repair_capacity decrease â‰¥0.15 vs baseline,
  - CAâ€‘125 <50% drop by cycleâ€‘3 or onâ€‘therapy rise.
- TODAY (no NGS): Show â€œAwaiting HRD; consider ordering HRD to unlock PARP gating.â€ No SAEâ€‘driven drug confidence yet.
- Finding ATR/CHK1 trials: use curated keywords (â€œATR inhibitorâ€, â€œCHK1 inhibitorâ€) + offline MoA tagging; never depend solely on LLM without review.

### C2) RAS/MAPK hotspot or high MAPK burden â†’ MEK/RAF trial candidates; deprioritize MEK monotherapy if absent
- Hotspot detection: use COSMIC/hardcoded list (e.g., KRAS G12C/G12D/G12V, NRAS Q61, BRAF V600E). SAE `hotspot_mutation` may assist but cannot override COSMIC.
- Conflict policy: hotspot present but MAPK burden low (<0.40) â‡’ show trials but no monotherapy boost; combos acceptable if other pathway rationale exists. Boost only if burden â‰¥0.40; full boost at â‰¥0.70.
- Deprioritize MEK monotherapy when burden <0.40 (âˆ’0.15) and show caution copy.
- TODAY: show â€œMAPK status: awaiting NGSâ€; do not surface MEK/RAF levers yet.

### C3) Essentiality high (DDR) â†’ strengthens PARP case; HR restoration pattern â†’ preemptive ATR/CHK1
- essentiality_signal source: Insights/depâ€‘map style dependency prior; treat as calibrated 0â€“1.
- Threshold: high â‰¥0.80; effect: add badge, confidence lift cap +0.03 only (avoid overâ€‘weighting single feature).
- Longitudinal logic: need â‰¥2 timepoints. HR restoration if HRD drop â‰¥10 AND dna_repair_capacity drop â‰¥0.15 OR emergence of RAD51 reactivation signature. Immediate alert; does not wait for radiographic progression.
- For treatmentâ€‘naive: show â€œNo longitudinal signal yet; set baseline and reâ€‘assess at weekâ€‘12/24.â€

### C4) Cross_resistance_risk high with prior taxane/ABCB1 â†’ avoid substrates; propose nonâ€‘substrates
- Risk model: max(
  - 0.8 if prior taxane with progression â‰¤6mo,
  - 0.7 if ABCB1 CNV>4 or expression proxy high,
  - else 0.3 baseline).
- ABCB1 inference before expression: use CNV if available; otherwise UNKNOWN (do not infer).
- Substrate lists: use PharmGKB/DrugBank curated classes; versioned; RUO.
- Nonâ€‘substrates: platinum, PARP, ATR/CHK1/WEE1 (verify perâ€‘agent substrate status; do not assume). Provide â€œlikely nonâ€‘substrateâ€ tag with source.
- TODAY (naive): show â€œCrossâ€‘resistance: low/unknown; no avoidance guidance yet.â€

### C5) Cohort_overlap low + confidence low â†’ push trials; high overlap â†’ lean standard with modest lift
- Definition: overlap of patient phenotype with literature/trial cohorts (disease, line, key biomarkers); proxy until cohort DB exists.
- Computation policy:
  - High (â‰¥0.70): disease + key biomarker archetype wellâ€‘represented (e.g., HRDâ€‘high HGSOC). Add +0.05 confidence and badge.
  - Moderate (0.40â€“0.69): no lift, no â€œpush trialsâ€ banner.
  - Low (<0.40): show â€œclinical trial recommendedâ€ banner; keep SOC but rank trials more prominently.
- Without cohort DB: use policy proxies and explicitly label as proxy.

### C6) Nextâ€‘test recommender (choose ONE first)
- Trigger: completeness L0/L1 or missing any of HRD/MSI/TMB.
- Priority order (Ayesha): 1) HRD (PARP gate), 2) ctDNA MSI/TMB + somatic HRR (IO and DDR combo considerations), 3) SLFN11 IHC (PARP sensitivity), 4) ABCB1 proxy if postâ€‘taxane scenario emerges.
- Messaging detail: use â€œdifferential branchesâ€ format (If positive â†’ X; If negative â†’ Y) with turnaround.

### C7) SAEâ€‘aligned trial ranking (mechanism fit)
- Vectors:
  - Patient `sae_mechanism_vector` = [DDR, MAPK, PI3K, VEGF, IO, Efflux] from SAE; L2â€‘normalize vectors before cosine.
  - Trial `moa_vector` from offline MoA tagging; store versioned; neutral if unknown.
- Fallback: if patient vector all zeros/unknown, mechanism_fit disabled (Î²=0) and explain â€œawaiting NGS; eligibilityâ€‘only ranking shown.â€
- Explanation: show breakdown (â€œDDR 0.82 Ã— PARP+ATR â†’ 0.95 fitâ€).
- Wrong MoA handling: human review gate; uncertain trials remain neutral.

### C8) Clinician hint tiles (UI)
- Max 4; prioritize: Next test â†’ Trials lever â†’ Monitoring â†’ Avoid (only when truly applicable).
- Preâ€‘NGS: test + monitoring + trials lever only. Postâ€‘NGS: enable â€œtry next/avoidâ€ based on SAE features.
- Copy tone: suggestive; include short reasons; link to source or provenance.

### C9) Mechanism Map UI (chips)
- Thresholds: Green â‰¥0.70; Yellow 0.40â€“0.69; Gray <0.40.
- IO special: Green if MSIâ€‘H; Gray if unknown; Red if MSIâ€‘S.
- Preâ€‘NGS: show gray chips with â€œAwaiting NGSâ€ overlay and tooltip clarifying meaning.

### C10) Preâ€‘computed care pathways
- Onâ€‘demand assembly (not batch). Criteria for â€œlineâ€‘ready ATR combo trialsâ€:
  - Recruiting; Phase II/III; â‰¤50 miles; mechanism_fit â‰¥0.60; exclusions manageable.
- Logistics factor: multiply combined score by proximity factor (1.0 â‰¤10 miles; 0.9 â‰¤50; 0.7 >100). Never hide a close, goodâ€‘fit trial.
- UI: by default collapse lowâ€‘fit mechanisms into â€œExplore moreâ€ with clear toggle to show all.

---

## Alignment With Ayesha
- TODAY (no NGS): deliver SOC + trials + CAâ€‘125 + Nextâ€‘test recommender; hide mechanism map; hints limited to testing/monitoring/logistics; no SAEâ€‘based efficacy claims.
- WHEN HRD returns: if â‰¥42, unlock PARP maintenance (with SAE rationale when available); if <42, surface ATR/CHK1 trials; keep RUO labels.
- IF resistance signals emerge: switch path per C1/C3 and show Resistance Playbook tiles.

---

## Provenance & Safety
- RUO labels on all hints; provenance logs include thresholds used, vectors, gating decisions, and data completeness level.
- No runtime LLM calls in clinical paths; offline LLM outputs humanâ€‘reviewed and versioned.
- All thresholds and policies are configurable constants; shipped with documentation and sources.

---

Status: APPROVED POLICY. Proceed to implement per debrief, honoring these guardrails.
